Dr. Michael Demeure, MD
General Surgery (Surgery Physician)
- Medicare participating
At a glance
- Medical school
- Hahnemann University College of Medicine (1983)
- Years since graduation
- 43
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 120
Licensed in California since 1988, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1983Medical school: Hahnemann University College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Surgery Physician primary
CA license G64786 (first issued 1988; current) · AZ license 15867
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hoag Memorial Hospital Presbyterian Newport Beach, CA
Medical groups
- Hoag Clinic (460 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 120
- Services billed
- 291
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| New patient office or other outpatient visit, 45-59 minutes | 47 | 47 |
| Established patient office or other outpatient visit, 30-39 minutes | 45 | 38 |
| Established patient office or other outpatient visit, 20-29 minutes | 41 | 40 |
| Ultrasound scan of head and neck soft tissue | 22 | 21 |
| New patient office or other outpatient visit, 30-44 minutes | 12 | 12 |
| Removal or exploration of parathyroid glands | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Newport Beach, CA | 65 |
| Oxycodone Hcl Other prescribers in Newport Beach, CA | 21 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 9 payments worth $4,353 in total to this clinician.
| Corcept Therapeutics | $3,737 |
|---|---|
| Aadi Bioscience, Inc. | $600 |
| Caris Mpi, Inc. | $16.22 |
| Compensation for services other than consulting (speaking, faculty) | $3,275 |
|---|---|
| Consulting Fee | $600 |
| Travel and Lodging | $307 |
| Food and Beverage | $171 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Corcept Therapeutics May 14, 2025 | Compensation for services other than consulting (speaking, faculty) Korlym · Endocrinology | $3,275 |
| Aadi Bioscience, Inc. Dec 19, 2025 | Consulting Fee Fyarro · Cancer | $600 |
| Corcept Therapeutics May 19, 2025 | Travel and Lodging Korlym · Endocrinology · travel to Milwaukee, WI · in-kind | $275 |
| Corcept Therapeutics May 19, 2025 | Travel and Lodging Korlym · Endocrinology · travel to Milwaukee, WI | $32.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $673,939 in research payments for these studies, mostly to the institutions running them.
- Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
Aadi Bioscience, Inc. · Completed · NCT05997056 - Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors
Taiho Oncology, Inc. - Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Mirati Therapeutics, Inc. · Active, not recruiting · NCT03785249 - Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Aadi Bioscience, Inc. · Completed · NCT05103358 - BAY 2731953, Prospective non-interventional study on TRK fusion cancer patients treated with larotrectinib
Bayer HealthCare Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.